News >

Expert Calls for Clinical Trial Referrals in Molecularly Targetable NSCLC

Angelica Welch
Published: Thursday, Oct 26, 2017

Regarding many of the other mutations and translocations that I spoke about, including HER2/neu, BRAF V600E, NTRK mutations—all of these need a lot of work to determine what would be a very good and, hopefully, less toxic therapy for many of these patients. 

What do you hope community oncologists took away from your talk?

First and foremost, I would like for people to be aware that there are different molecular targets that do occur in NSCLC. I hope that it prompts them to test for those molecular abnormalities. Up to approximately 25% of patients with NSCLC can harbor a targetable mutation. I also hope that they realize that many of these molecular targets have not been fully worked out; there are a lot of resistance mechanisms that can develop. Also, I hope that they send patients for clinical trials.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication